| Overview |
| bs-23615R-FITC |
| CD27 Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD27 |
| 101-200/250 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 21940 |
| P41272 |
| Cell membrane |
| CD 27; Cd27; CD27 antigen; CD27 molecule; CD27_MOUSE; CD27L receptor; LPFS2; MGC20393; OTTHUMP00000238557; S152; T cell activation antigen CD27; T cell antivation antigen S152; T-cell activation antigen CD27; T14; TNFRSF 7; TNFRSF7; TNFSF7; Tp 55; Tp55; Tumor necrosis factor receptor superfamily member 7. |
| The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-kappaB and MAPK8/JNK. Adaptor proteins TRAF2 and TRAF5 have been shown to mediate the signaling process of this receptor. CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor. [provided by RefSeq, Jul 2008] |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz